OVA-E1 peptide contains a defined sequence of polar, aromatic, and charged residues that promote diverse secondary-structure motifs. Researchers use it to examine antigenic determinants, peptide folding dynamics, and residue-specific interactions. The sequence's balanced polarity aids studies of conformational transitions. Its architecture supports detailed biophysical profiling.
CAT No: R2407
CAS No:153316-01-9
Synonyms/Alias:OVA-E1 peptide;153316-01-9;(2S,5S,8S,11S,14S,17S,20S,23S)-23-Amino-14-(2-amino-2-oxoethyl)-5-(4-aminobutyl)-11-benzyl-17,20-di((S)-sec-butyl)-8-(2-carboxyethyl)-2-isobutyl-4,7,10,13,16,19,22-heptaoxo-3,6,9,12,15,18,21-heptaazahexacosanedioic acid;HY-P2319;AKOS040756882;DA-76497;CS-0129511;(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S,3S)-2-[[(2S,3S)-2-[[(2S)-2-amino-4-carboxybutanoyl]amino]-3-methylpentanoyl]amino]-3-methylpentanoyl]amino]-4-oxobutanoyl]amino]-3-phenylpropanoyl]amino]-4-carboxybutanoyl]amino]hexanoyl]amino]-4-methylpentanoic acid;
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More